{"id":58641,"date":"2026-03-03T13:30:31","date_gmt":"2026-03-03T05:30:31","guid":{"rendered":"https:\/\/flcube.com\/?p=58641"},"modified":"2026-04-10T23:39:44","modified_gmt":"2026-04-10T15:39:44","slug":"roches-fenebrutinib-hits-phase-iii-endpoint-in-ms-btk-inhibitor-cuts-relapse-rate-51-vs-standard-of-care","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58641","title":{"rendered":"Roche&#8217;s Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care"},"content":{"rendered":"\n<p><strong>Roche (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX:\u202fROG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS:\u202fRHHBY<\/a>)<\/strong> announced that the <strong>pivotal Phase III FENhance\u202f1 study<\/strong> for <strong>fenebrutinib<\/strong> in <strong>relapsing multiple sclerosis (RMS)<\/strong> has met its <strong>primary endpoint<\/strong> with <strong>clinically meaningful results<\/strong>. The <strong>non\u2011covalent BTK inhibitor<\/strong> significantly reduced the <strong>annualized relapse rate (ARR) by 51%<\/strong> compared to <strong>teriflunomide<\/strong> over \u2265\u202f96 weeks, aligning with the <strong>59% ARR reduction<\/strong> observed in the <strong>FENhance\u202f2 study<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-iii-results-fenhance-program\">Phase III Results \u2013 FENhance Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Primary Endpoint Result<\/th><th>Clinical Translation<\/th><\/tr><\/thead><tbody><tr><td><strong>FENhance\u202f1<\/strong><\/td><td><strong>51% ARR reduction<\/strong> vs. teriflunomide<\/td><td>~\u202f1 relapse every 17 years<\/td><\/tr><tr><td><strong>FENhance\u202f2<\/strong><\/td><td><strong>59% ARR reduction<\/strong> vs. teriflunomide<\/td><td>Consistent efficacy across trials<\/td><\/tr><tr><td><strong>Combined Impact<\/strong><\/td><td>~\u202f55% average ARR reduction<\/td><td>Transformative disease control<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-fenebrutinib\">Drug Profile \u2013 Fenebrutinib<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Class<\/strong><\/td><td>Non\u2011covalent Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/td><\/tr><tr><td><strong>Target Cells<\/strong><\/td><td>B cells + microglial cells (CNS resident immune cells)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Systemic immune modulation + CNS\u2011penetrant anti\u2011inflammatory action<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td><strong>Blood\u2011brain barrier penetration<\/strong> \u2013 targets chronic CNS inflammation<\/td><\/tr><tr><td><strong>Comparison<\/strong><\/td><td>Non\u2011covalent (reversible) vs. covalent BTK inhibitors (evobrutinib, rilzabrutinib)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BTK in MS Validation:<\/strong> The <strong>FENhance program success<\/strong> validates <strong>BTK inhibition as a disease\u2011modifying mechanism<\/strong> in multiple sclerosis, potentially expanding beyond anti\u2011CD20 antibodies (ocrelizumab, ofatumumab) and S1P modulators.<\/li>\n\n\n\n<li><strong>CNS\u2011Penetrant Advantage:<\/strong> Fenebrutinib&#8217;s <strong>blood\u2011brain barrier crossing<\/strong> enables <strong>direct targeting of microglial\u2011mediated chronic inflammation<\/strong> within the CNS\u2014a hypothesized driver of progressive disability not addressed by peripheral immunomodulators.<\/li>\n\n\n\n<li><strong>Teriflunomide Benchmark:<\/strong> The <strong>51\u201159% ARR reduction vs. teriflunomide<\/strong> (established oral standard) positions fenebrutinib as a <strong>best\u2011in\u2011class oral MS therapy<\/strong>, potentially displacing first\u2011line oral options (dimethyl fumarate, teriflunomide).<\/li>\n\n\n\n<li><strong>Progressive MS Potential:<\/strong> The <strong>CNS\u2011penetrant mechanism<\/strong> supports ongoing evaluation in <strong>primary progressive MS (PPMS)<\/strong> and <strong>secondary progressive MS (SPMS)<\/strong>, where unmet need remains highest.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>MS Market Size<\/strong><\/td><td>~\u202f$25\u202fbillion globally; dominated by anti\u2011CD20 mAbs (Ocrevus, Kesimpta) with growing oral segment<\/td><\/tr><tr><td><strong>BTK Competitive Landscape<\/strong><\/td><td>Merck&#8217;s evobrutinib (discontinued due to liver toxicity); Sanofi&#8217;s rilzabrutinib (ITP approved, MS not pursued); Roche&#8217;s fenebrutinib now leads BTK\u2011MS development<\/td><\/tr><tr><td><strong>Oral MS Preference<\/strong><\/td><td>Patient demand for non\u2011injectable options; fenebrutinib offers efficacy approaching anti\u2011CD20s with oral convenience<\/td><\/tr><tr><td><strong>Progressive MS Opportunity<\/strong><\/td><td>~\u202f50% of RMS patients transition to SPMS; CNS\u2011penetrant BTK inhibition may address unmet progressive disability need<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory submission timelines, approval expectations, and progressive MS development for fenebrutinib. Actual results may differ due to risks including long\u2011term safety monitoring, competitive anti\u2011CD20 entrenchement, and progressive MS trial design challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) announced that the pivotal Phase III FENhance\u202f1 study for fenebrutinib in relapsing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,940,24,163,939],"class_list":["post-58641","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-otcmkts-rhhby","tag-rare-orphan-disease-drugs","tag-roche","tag-swx-rog"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche&#039;s Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) announced that the pivotal Phase III FENhance\u202f1 study for fenebrutinib in relapsing multiple sclerosis (RMS) has met its primary endpoint with clinically meaningful results. The non\u2011covalent BTK inhibitor significantly reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide over \u2265\u202f96 weeks, aligning with the 59% ARR reduction observed in the FENhance\u202f2 study.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58641\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche&#039;s Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care\" \/>\n<meta property=\"og:description\" content=\"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) announced that the pivotal Phase III FENhance\u202f1 study for fenebrutinib in relapsing multiple sclerosis (RMS) has met its primary endpoint with clinically meaningful results. The non\u2011covalent BTK inhibitor significantly reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide over \u2265\u202f96 weeks, aligning with the 59% ARR reduction observed in the FENhance\u202f2 study.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58641\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T05:30:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-10T15:39:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58641#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58641\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche&#8217;s Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care\",\"datePublished\":\"2026-03-03T05:30:31+00:00\",\"dateModified\":\"2026-04-10T15:39:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58641\"},\"wordCount\":413,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"OTCMKTS: RHHBY\",\"Rare \\\/ orphan disease drugs\",\"Roche\",\"SWX: ROG\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58641#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58641\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58641\",\"name\":\"Roche's Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-03T05:30:31+00:00\",\"dateModified\":\"2026-04-10T15:39:44+00:00\",\"description\":\"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) announced that the pivotal Phase III FENhance\u202f1 study for fenebrutinib in relapsing multiple sclerosis (RMS) has met its primary endpoint with clinically meaningful results. The non\u2011covalent BTK inhibitor significantly reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide over \u2265\u202f96 weeks, aligning with the 59% ARR reduction observed in the FENhance\u202f2 study.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58641#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58641\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58641#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche&#8217;s Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche's Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care - Insight, China&#039;s Pharmaceutical Industry","description":"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) announced that the pivotal Phase III FENhance\u202f1 study for fenebrutinib in relapsing multiple sclerosis (RMS) has met its primary endpoint with clinically meaningful results. The non\u2011covalent BTK inhibitor significantly reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide over \u2265\u202f96 weeks, aligning with the 59% ARR reduction observed in the FENhance\u202f2 study.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58641","og_locale":"en_US","og_type":"article","og_title":"Roche's Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care","og_description":"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) announced that the pivotal Phase III FENhance\u202f1 study for fenebrutinib in relapsing multiple sclerosis (RMS) has met its primary endpoint with clinically meaningful results. The non\u2011covalent BTK inhibitor significantly reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide over \u2265\u202f96 weeks, aligning with the 59% ARR reduction observed in the FENhance\u202f2 study.","og_url":"https:\/\/flcube.com\/?p=58641","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-03T05:30:31+00:00","article_modified_time":"2026-04-10T15:39:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58641#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58641"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche&#8217;s Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care","datePublished":"2026-03-03T05:30:31+00:00","dateModified":"2026-04-10T15:39:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58641"},"wordCount":413,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","OTCMKTS: RHHBY","Rare \/ orphan disease drugs","Roche","SWX: ROG"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58641#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58641","url":"https:\/\/flcube.com\/?p=58641","name":"Roche's Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-03T05:30:31+00:00","dateModified":"2026-04-10T15:39:44+00:00","description":"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) announced that the pivotal Phase III FENhance\u202f1 study for fenebrutinib in relapsing multiple sclerosis (RMS) has met its primary endpoint with clinically meaningful results. The non\u2011covalent BTK inhibitor significantly reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide over \u2265\u202f96 weeks, aligning with the 59% ARR reduction observed in the FENhance\u202f2 study.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58641#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58641"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58641#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche&#8217;s Fenebrutinib Hits Phase III Endpoint in MS \u2013 BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58641"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58641\/revisions"}],"predecessor-version":[{"id":58644,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58641\/revisions\/58644"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}